Cocoa Prices Plunge on Projections for a Larger 2025/26 Ghana Cocoa Crop
Cocoa prices plunged to 1-week lows Tuesday due to the outlook for larger cocoa production in Ghana, the world's second-largest cocoa producer. The Ghana Cocoa Board on Tuesday projected the 2025/26 Ghana cocoa crop to increase by +8.3% y/y to 650,000 from 600,000 MT in 2024/25.
Arabica Coffee Pressured by Beneficial Brazil Rain
Cocoa Prices Plunge on Expectations of a Bigger Ghana Cocoa Crop
Sugar Prices Plummet on Weak Demand and Ample Supplies
Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now!
The rebound in current cocoa inventories is also bearish for prices. Since falling to a 21-year low of 1,263,493 bags on January 24, ICE-monitored cocoa inventories held in US ports climbed to a 9-3/4 month high of 2,363,861 bags on June 18.
Cocoa prices have support from concerns about tighter cocoa supplies from the Ivory Coast. Monday's government data showed that Ivory Coast farmers shipped 1.698 MMT of cocoa to ports this marketing year from October 1 to June 29, up +6.8% from last year but down from the much larger +35% increase seen in December. There are reports that heavy rain in the Ivory Coast is keeping cocoa growers off their farms and is disrupting the ongoing mid-crop cocoa harvest.
Signs of smaller cocoa exports are supportive of cocoa prices, following last Wednesday's news that Nigerian May cocoa exports fell by -29% y/y to 14,110 MT. Nigeria is the world's fourth-largest exporter of cocoa.
In late May, NY cocoa rallied to a 5-month nearest-futures high on concerns about weather in West Africa. Despite the recent rain in West Africa, drought still covers more than a third of Ghana and the Ivory Coast, according to the African Flood and Drought Monitor.
Cocoa prices also have support due to quality concerns regarding the Ivory Coast's mid-crop cocoa, which is currently being harvested through September. Cocoa processors are complaining about the quality of the crop and have rejected truckloads of Ivory Coast cocoa beans. Processors reported that about 5% to 6% of the mid-crop cocoa in each truckload is of poor quality, compared with 1% during the main crop. According to Rabobank, the poor quality of the Ivory Coast's mid-crop is partly attributed to late-arriving rain in the region, which limited crop growth. The mid-crop is the smaller of the two annual cocoa harvests, which typically starts in April. The average estimate for this year's Ivory Coast mid-crop is 400,000 MT, down -9% from last year's 440,000 MT.
Concern about consumer demand for cocoa and cocoa products is bearish for cocoa, driven by fears that tariffs will exacerbate already high cocoa prices. On April 10, Barry Callebaut AG, one of the world's largest chocolate makers, reduced its annual sales guidance due to high cocoa prices and tariff uncertainty. Also, chocolate maker Hershey Co. recently reported that Q1 sales fell by 14% and said it anticipated $15-$20 million in tariff costs in Q2, which will boost chocolate prices and further weigh on consumer demand. Mondelez International reported weaker-than-expected Q1 sales, stating that consumers are cutting back on snack purchases due to economic uncertainty and high chocolate prices.
Weaker demand from cocoa processors was seen in Q1. Q1 North American cocoa grindings fell -2.5% y/y to 110,278 MT. Q1 European cocoa grindings fell -3.7% y/y to 353,522 MT. Q1 Asian cocoa grinding fell -3.4% y/y to 213,898 MT.
On May 30, the International Cocoa Organization (ICCO) revised its 2023/24 global cocoa deficit to -494,000 MT from a February estimate of -441,000 MT, the largest deficit in over 60 years. ICCO said 2023/24 cocoa production fell -13.1% y/y to 4.380 MMT. ICCO said the 2023/24 global cocoa stocks/grindings ratio fell to a 46-year low of 27.0%. Looking ahead to 2024/25, ICCO on February 28 forecasted a global cocoa surplus of 142,000 MT for 2024/25, the first surplus in four years. ICCO also projected that 2024/25 global cocoa production will rise +7.8% y/y to 4.84 MMT.
On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
This ‘Strong Buy' Pharma Stock Is Surging to New Highs
Insmed (INSM) shows strong technical momentum, hitting a new 52-week high on Aug. 18. INSM has a 100% 'Buy' opinion from Barchart with impressive recent gains. Revenue is projected to grow nearly 29% this year and 126% next year, with earnings growth expected to accelerate in 2026. Wall Street analysts are mostly bullish, but there is a wide range of price targets on INSM here. Today's Featured Stock Valued at $26.9 billion, Insmed (INSM) is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations. The group is patients with non-tuberculous lung infections. The second is cystic fibrosis patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, an inhaled treatment for pulmonary arterial hypertension. What I'm Watching I found today's Chart of the Day by using Barchart's powerful screening functions to sort for stocks with the highest technical buy signals; superior current momentum in both strength and direction; and a Trend Seeker 'buy' signal. I then used Barchart's Flipcharts feature to review the charts for consistent price appreciation. INSM checks those boxes. Since the Trend Seeker signaled a buy on June 3, the stock gained 74.15%. More News from Barchart Trade the Warren Buffett Rally in UnitedHealth Stock With This High-Reward, Low-Risk Options Strategy Apple Expects $1.1 Billion Tariff Hit in 4th Quarter After $800 Million Q3 Hit; CEO Tim Cook Warns 'Many Factors That Could Change' Cathie Wood Is Buying BLSH Stock After the Bullish IPO. Should You? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. INSM Price vs. Daily Moving Averages: Barchart Technical Indicators for Insmed Editor's Note: The technical indicators below are updated live during the session every 20 minutes and can therefore change each day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the website when you read this report. These technical indicators form the Barchart Opinion on a particular stock. Insmed shares hit a new 52-week high on Aug. 18, touching $130.13 in intraday trading. Insmed has a Weighted Alpha of +67.81. INSM has an 100% 'Buy' opinion from Barchart. The stock gained 64.02% over the past year. INSM has its Trend Seeker 'Buy' signal intact. Insmed is trading above its 20-, 50-, and 100-day moving averages. The stock made 15 new highs and gained 24.09% in the last month. Relative Strength Index (RSI) is at 83.71%. There's a technical support level around $126.22. Don't Forget the Fundamentals $26.9 billion market capitalization. Revenue is projected to grow 28.82% this year and another 126.13% next year. Earnings are estimated to increase 0.35% this year and an additional 29.14% next year. Analyst and Investor Sentiment on Insmed I don't buy stocks because everyone else is buying, but I do realize that if major firms and investors are dumping a stock, it's hard to make money swimming against the tide. It looks like Wall Street analysts are bullish on INSM, but CFRA's MarketScope Advisor is not. The Wall Street analysts tracked by Barchart have issued 16 'Strong Buy,' 1 'Moderate Buy,' and 1'Hold' opinion on the stock. Their price targets are between $110-$240 – a very wide spread. Value Line gives the stock its average rating. CFRA's MarketScope Advisor gives the stock a 'Sell' rating. Morningstar thinks the stock is fairly valued. 352 individual investors on Motley Fool think the stock will beat the market while 108 think it won't. 4,010 investors monitor the stock on Seeking Alpha, which rates the stock a 'Hold.' The Bottom Line on Insmed Insmed currently has momentum and is hitting new highs. I caution that INSM is volatile and even speculative in the current environment, which means investors should use strict risk management and stop-loss strategies. Today's Chart of the Day was written by Jim Van Meerten. Read previous editions of the daily newsletter here. Additional disclosure: The Barchart of the Day highlights stocks that are experiencing exceptional current price appreciation. They are not intended to be buy recommendations as these stocks are extremely volatile and speculative. Should you decide to add one of these stocks to your investment portfolio it is highly suggested you follow a predetermined diversification and moving stop loss discipline that is consistent with your personal investment risk tolerance. On the date of publication, Jim Van Meerten did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Coffee Prices Just Hit 2-Month Highs. How Much Higher Can They Go Here?
December coffee futures (KCZ25) present a buying opportunity on more price strength. See on the daily bar chart for December arabica coffee futures that prices have rallied from the July low, have just hit a two-month high and prices are trending higher. See, too, at the bottom of the chart that the moving average convergence divergence (MACD) indicator is in a bullish posture as the red MACD line is above the blue trigger line and both lines are trending higher. More News from Barchart Coffee Prices Give Up Early Gains on Comments From Brazil's Ag Minister Below-Average Rainfall in Brazil Supports Arabica Coffee Prices Soybeans Are Heating Up. Here's What Could Take Them Much Higher. Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Fundamentally, less-than-ideal growing weather in major coffee-producing countries has crimped supplies. Brazil and Vietnam have seen major droughts that have severely impacted crop yields. Meantime, world demand for coffee continues to rise steadily, especially in China. Supply chain disruptions have also limited coffee supplies on the world market in recent years. A move in December coffee futures above chart resistance at today's high of 344.70 cents would become a buying opportunity. The upside price objective would be 405.00 cents, or above. Technical support, for which to place a protective sell stop just below, is located at 320.00 cents. IMPORTANT NOTE: I am not a futures broker and do not manage any trading accounts other than my own personal account. It is my goal to point out to you potential trading opportunities. However, it is up to you to: (1) decide when and if you want to initiate any trades and (2) determine the size of any trades you may initiate. Any trades I discuss are hypothetical in nature. Here is what the Commodity Futures Trading Commission (CFTC) has said about futures trading (and I agree 100%): Trading commodity futures and options is not for everyone. IT IS A VOLATILE, COMPLEX AND RISKY BUSINESS. Before you invest any money in futures or options contracts, you should consider your financial experience, goals and financial resources, and know how much you can afford to lose above and beyond your initial payment to a broker. You should understand commodity futures and options contracts and your obligations in entering into those contracts. You should understand your exposure to risk and other aspects of trading by thoroughly reviewing the risk disclosure documents your broker is required to give you. On the date of publication, Jim Wyckoff did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Do Wall Street Analysts Like Deere & Company Stock?
With a market cap of $133 billion, Deere & Company (DE) is the world's largest producer of agricultural equipment, best known for its iconic John Deere brand with the signature green and yellow design. The company operates globally across four segments: Production and Precision Agriculture; Small Agriculture and Turf; Construction and Forestry; and Financial Services. Shares of the Moline, Illinois-based company have outperformed the broader market over the past 52 weeks. DE stock has climbed 31.9% over this time frame, while the broader S&P 500 Index ($SPX) has returned 16.1%. Moreover, shares of the company are up 16.1% on a YTD basis, compared to SPX's 9.7% gain. More News from Barchart Trade the Warren Buffett Rally in UnitedHealth Stock With This High-Reward, Low-Risk Options Strategy Apple Expects $1.1 Billion Tariff Hit in 4th Quarter After $800 Million Q3 Hit; CEO Tim Cook Warns 'Many Factors That Could Change' Cathie Wood Is Buying BLSH Stock After the Bullish IPO. Should You? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Focusing more closely, the agricultural equipment manufacturer stock has also outpaced the Industrial Select Sector SPDR Fund's (XLI) 18.4% increase over the past 52 weeks. Despite reporting better-than-expected Q3 2025 net income of $4.75 and adjusted revenue of $10.4 billion, Deere's shares tumbled 6.8% on Aug. 14 as profits dropped sharply from $6.29 per share a year earlier. The company warned its tariff impact would reach nearly $600 million for the year, with Q3 tariffs alone costing about $200 million. Deere also cut the high end of its annual profit forecast to $5.25 billion and reported operating profits in its core tractor and construction units had roughly halved, highlighting margin pressure and weak demand. For the fiscal year ending in October 2025, analysts expect Deere & Company's EPS to decline 26.9% year-over-year to $18.72. However, the company's earnings surprise history is promising. It topped the consensus estimates in the last four quarters. Among the 22 analysts covering the stock, the consensus rating is a 'Moderate Buy.' That's based on 11 'Strong Buy' ratings, one 'Moderate Buy,' and 10 'Holds.' On Aug, 19, Evercore ISI analyst David Raso lowered Deere's price target to $491 while maintaining an 'In Line" rating. As of writing, the stock is trading below the mean price target of $543.31. The Street-high price target of $750 implies a potential upside of 51.2% from the current price levels. On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
